drugset / Trial / NCT00271219

RCT Comparing Methadone and Buprenorphine in Pregnant Women

NCT00271219 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Children born to women who abuse drugs have a high risk of being born with birth defects and developmental problems. Methadone is a drug that is commonly used for treating opioid dependence. However, its use by a pregnant woman can cause severe withdrawal symptoms in a newborn because of the prenatal exposure. The purpose of this study is to evaluate the effectiveness of buprenorphine, another drug, versus methadone in reducing withdrawal symptoms in children born to opioid-dependent women.

Timeline

Start
2005-07
Primary completion
2009-08
Completion
2010-06

Outcome

Mixed primary results

paper Primary outcomes were the number of neonates requiring treatment for NAS, the peak NAS score PMID 21142534 ↗

paper the former group required significantly less morphine (mean dose, 1.1 mg vs. 10.4 mg; P<0.0091) PMID 21142534 ↗

paper had a significantly shorter hospital stay (10.0 days vs. 17.5 days, P<0.0091) PMID 21142534 ↗

paper had a significantly shorter duration of treatment for the neonatal abstinence syndrome (4.1 days vs. 9.9 days, P<0.003125) PMID 21142534 ↗

paper There were no significant differences between groups in other primary or secondary outcomes PMID 21142534 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 2 mg Other
Subject Buprenorphine Other / unclassified 32 mg Other
Comparator Methadone Other / unclassified 20 mg Oral
Comparator Methadone Other / unclassified 140 mg Oral